Brief: Sprint Bioscience Reports Positive Proof-Of-Concept Results From Program In CKD
01/04/2026 07:06
April 1 (Reuters) - Sprint Bioscience AB SPRINT.ST: ANNOUNCES POSITIVE PROOF-OF-CONCEPT RESULTS FROM NNMT PROGRAM IN CKD PROGRAM IS NOW BEING EXPANDED BEYOND SOLID TUMORS TO ALSO INCLUDE CHRONIC KIDNEY DISEASE Source text: ID:nMFN21XN5r Further company coverage: SPRINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln